Liver Disease
LBS-009 is an oral anti-RBP4 therapy in preclinical development for NAFLD, NASH, and type 2 diabetes. It is designed to compete with retinol for binding to RBP4, the primary carrier of vitamin A from the liver to extra-hepatic tissues.

Belite Bio is a clinical-stage biopharmaceutical company developing oral therapies targeting retinol binding protein 4 for degenerative retinal diseases.
belitebio.comCrawled Oct 15, 2026
LBS-009 is an oral anti-RBP4 therapy in preclinical development for NAFLD, NASH, and type 2 diabetes. It is designed to compete with retinol for binding to RBP4, the primary carrier of vitamin A from the liver to extra-hepatic tissues.
Tinlarebant (LBS-008) is a once-a-day oral therapy intended to reduce eye toxins that cause STGD1 and contribute to GA, retinal degenerative diseases that eventually lead to blindness.
The company says Tinlarebant (LBS-008), developed from its RBP4 intellectual property portfolio, is intended to reduce toxic vitamin A byproducts in the retina and is being evaluated in a Phase 3 study.
Tinlarebant (LBS-008) is a once-a-day oral therapy intended to reduce eye toxins that cause Stargardt disease (STGD1) and contribute to geographic atrophy (GA).
LBS-009 is an oral anti-RBP4 therapy targeting liver disease, including NAFLD and NASH, and type 2 diabetes (T2D). It is designed to compete with retinol for binding to RBP4, the primary carrier of vitamin A from the liver to extra-hepatic target tissues.
Dr. Tom Lin (Yu-Hsin Lin) is founder, chairman, and chief executive officer of Belite Bio and founder of Lin BioScience, Inc., Belite Bio’s ultimate controlling shareholder.
The company is a clinical-stage biopharmaceutical drug development company focused on therapeutics for ophthalmology, liver disease, and diabetes. Its lead candidate, Tinlarebant (LBS-008), targets STGD1 and GA.
The company’s pipeline is built on its Retinol Binding Protein 4 (RBP4) intellectual property portfolio and focuses on degenerative retinal diseases, liver disease, and diabetes.
The company’s pipeline is built on its RBP4 (Retinol Binding Protein 4) intellectual property portfolio and focuses on blindness, liver disease, and diabetes.
The company lists its address as 5820 Oberlin Drive, Suite 101, San Diego CA 92121.